Spinout News

Freeline initiates dosing of second cohort in MARVEL-1 trial of FLT190 gene therapy candidate for people with Fabry disease

5 October 2022


Freeline Therapeutics Holdings plc (Nasdaq: FRLN) has announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1 clinical trial of FLT190 in Fabry disease, a debilitating inherited disorder that leads to progressive organ damage and can result in early death as a result of a harmful build-up of fat in cells due to an enzyme deficiency.

Freeline recently reached alignment with the U.S. Food and Drug Administration to dose patients in MARVEL-1 in the United States. Efficacy and safety data from the first dose cohort of MARVEL-1 (in which patients received 7.5e11 vg/kg of FLT190) supported progression to the second, mid-dose cohort (1.5e12 vg/kg).

Read the full story from Freeline here.